TARGET RESEARCH ARTICLES

TARGET RESEARCH VIDEOS

Gene-edited T cells targeting PD-1 and TIGIT are redefining approaches to cancer therapy. Explore how cell engineering and integrated genomic workflows uncover critical insights into T cell function.

Panelists debate whether NAMS can replace 10% of animal testing for regulatory submissions by 2030. Shashi asserts that big pharma is already reducing animal use, while Samantha cites the EU’s success in cosmetics and FDA’s roadmap for monoclonals. Zaher predicts over 50% replacement by 2030, citing OECD updates and liver injury data.

Zaher frames the urgency of NAMS adoption by highlighting the staggering 92% drug failure rate in clinical trials despite animal testing. He explains how interdisciplinary convergence and AI are accelerating the shift toward human-relevant models, positioning NAMS as a solution to systemic inefficiencies in drug development.

Collaboration across sites is critical in the journey from development to manufacturing. Watch to discover how to accelerate cross-site collaboration with simple assay transfer.

TARGET RESEARCH ARTICLES. APP NOTES, CASE STUDIES. & WHITE PAPERS

TARGET RESEARCH SOLUTIONS

  • Macrocycles expand drug discovery into previously inaccessible targets. With validated success and flexible approaches, they provide a powerful path for tackling the most challenging biology.

  • CHO cells have been the workhorse for protein and antibody manufacturing. The major advantages of CHO include robust growth, hardiness in suspension culture, stellar protein production and secretion, and a long track record.

  • HEK293 cells have been the most popular mammalian transient production platform. The primary advantage of HEK293 cells is transfection efficiency.

  • The demand for high-throughput antibodies has exponentially increased over the last couple of years and has rapidly accelerated the antibody screening process.

  • E. coli is often the system of choice for biomanufacturing because of its amenability to genetic manipulation, low production cost, and rapid timelines for bioexpression.

  • Curia provides a wide range of biochemical and cell-based bioassay workflows to support Discovery, Research & Development as well as cGxP therapeutic testing campaigns

  • We deliver custom assay development, screening, potency, and selectivity testing services for the pharmaceutical, biopharmaceutical, and agrochemical industries.

  • Evaluating small and large molecule therapeutics within cellular environments is essential to understanding their efficacy, potency, and safety within a complex biological system.

  • Curia’s expert scientists use advanced technology to produce and analyze high-quality recombinant proteins.

  • Curia’s discovery biology team accelerates your program toward the clinic and commercialization with our best-in-class, customizable solutions.

  • At Curia, our team of expert protein chemists and structural biologists brings the advanced experience and technology needed to support all your structural biology services needs.

  • High‑throughput scNMT‑seq offers a powerful way to map methylation and transcriptional activity. Learn about strategies that cut variability and support dependable multi‑omics datasets.

  • Generate human-relevant data with an Organ-Chip system that combines automation, imaging, and cost efficiency for faster, more confident insights for drug development and complex biological studies.

  • With 12 independent Emulations in one consumable, Chip-Array optimizes workflows and reduces cell requirements—delivering scalable, physiologically relevant models for advanced research.